{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/PRQR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T10:12:13.836Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3959,"canonical_name":"ProQR Therapeutics N.V.","cik":"0001612940","uei":null,"lei":null,"duns":null,"ticker":"PRQR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35},"count":35,"timeline":[{"ts":"2026-09-23","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-09-23","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-109819","accession_number":"0001104659-26-109819","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-09-09","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-106138","accession_number":"0001104659-26-106138","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-08-13","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-095422","accession_number":"0001104659-26-095422","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-08-13","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-095425","accession_number":"0001104659-26-095425","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-08-03","url_slug":"/sec/cik-0001612940/4/0001104659-26-089780","accession_number":"0001104659-26-089780","importance":30},{"ts":"2026-07-31","kind":"sec.insider.p","reporter":"de Boer Daniel Anton","title":"Chief Executive Officer","shares":200000,"price_per_share":1.7698,"usd_value":353960,"security_title":"Ordinary Shares","importance":50.35396},{"ts":"2026-07-29","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — ProQR Therapeutics N.V. — 2026-07-29","url_slug":"/sec/cik-0001612940/schedule-13d-a/0001104659-26-088126","accession_number":"0001104659-26-088126","importance":70},{"ts":"2026-07-29","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — ProQR Therapeutics N.V. — 2026-07-29","url_slug":"/sec/cik-0001612940/schedule-13g/0001716774-26-000021","accession_number":"0001716774-26-000021","importance":55},{"ts":"2026-07-24","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ProQR Therapeutics N.V. — 2026-07-24","url_slug":"/sec/cik-0001612940/schedule-13g-a/0000059478-26-000071","accession_number":"0000059478-26-000071","importance":30},{"ts":"2026-07-21","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-07-21","url_slug":"/sec/cik-0001612940/4/0001104659-26-085234","accession_number":"0001104659-26-085234","importance":30},{"ts":"2026-07-17","kind":"sec.insider.p","reporter":"Filius Bart","title":"","shares":150000,"price_per_share":1.7195,"usd_value":257925,"security_title":"Ordinary Shares","importance":50.257925},{"ts":"2026-07-17","kind":"sec.insider.150000","reporter":"Filius Bart","title":null,"shares":150000,"price_per_share":1.7195,"usd_value":257925,"security_title":"Ordinary Shares","importance":15.257925},{"ts":"2026-07-15","kind":"sec.filing","form_type":"424B5","title":"424B5 — ProQR Therapeutics N.V. — 2026-07-15","url_slug":"/sec/cik-0001612940/424b5/0001104659-26-083906","accession_number":"0001104659-26-083906","importance":30},{"ts":"2026-07-15","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — ProQR Therapeutics N.V. — 2026-07-15","url_slug":"/sec/cik-0001612940/effect/9999999995-26-002315","accession_number":"9999999995-26-002315","importance":30},{"ts":"2026-07-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ProQR Therapeutics N.V. — 2026-07-15","url_slug":"/sec/cik-0001612940/schedule-13g-a/0001104659-26-083818","accession_number":"0001104659-26-083818","importance":30},{"ts":"2026-07-13","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-07-13","url_slug":"/sec/cik-0001612940/4/0001104659-26-082890","accession_number":"0001104659-26-082890","importance":30},{"ts":"2026-07-09","kind":"sec.insider.p","reporter":"de Boer Daniel Anton","title":"Chief Executive Officer","shares":150000,"price_per_share":1.74,"usd_value":261000,"security_title":"Ordinary Shares","importance":50.261},{"ts":"2026-07-09","kind":"sec.insider.150000","reporter":"de Boer Daniel Anton","title":"Chief Executive Officer","shares":150000,"price_per_share":1.74,"usd_value":261000,"security_title":"Ordinary Shares","importance":15.261},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-07-08","url_slug":"/sec/cik-0001612940/4/0001104659-26-081762","accession_number":"0001104659-26-081762","importance":30},{"ts":"2026-07-07","kind":"sec.insider.p","reporter":"de Boer Daniel Anton","title":"Chief Executive Officer","shares":150000,"price_per_share":1.59,"usd_value":238500,"security_title":"Ordinary Shares","importance":50.2385},{"ts":"2026-07-06","kind":"sec.filing","form_type":"F-3","title":"F-3 — ProQR Therapeutics N.V. — 2026-07-06","url_slug":"/sec/cik-0001612940/f-3/0001104659-26-080750","accession_number":"0001104659-26-080750","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — ProQR Therapeutics N.V. — 2026-06-30","url_slug":"/sec/cik-0001612940/schedule-13d-a/0001104659-26-079415","accession_number":"0001104659-26-079415","importance":70},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-06-30","url_slug":"/sec/cik-0001612940/4/0001104659-26-079316","accession_number":"0001104659-26-079316","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4/A","title":"4/A — ProQR Therapeutics N.V. — 2026-06-30","url_slug":"/sec/cik-0001612940/4-a/0001104659-26-079319","accession_number":"0001104659-26-079319","importance":30},{"ts":"2026-06-26","kind":"sec.insider.p","reporter":"Filius Bart","title":"","shares":150000,"price_per_share":1.54,"usd_value":231000,"security_title":"Ordinary Shares","importance":50.231},{"ts":"2026-06-26","kind":"sec.filing","form_type":"424B5","title":"424B5 — ProQR Therapeutics N.V. — 2026-06-26","url_slug":"/sec/cik-0001612940/424b5/0001104659-26-077891","accession_number":"0001104659-26-077891","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-06-26","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-077892","accession_number":"0001104659-26-077892","importance":30},{"ts":"2026-06-26","kind":"sec.insider.150000","reporter":"Filius Bart","title":null,"shares":150000,"price_per_share":1.54,"usd_value":231000,"security_title":"Ordinary Shares","importance":15.231},{"ts":"2026-06-25","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-06-25","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-077506","accession_number":"0001104659-26-077506","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — ProQR Therapeutics N.V. — 2026-06-03","url_slug":"/sec/cik-0001612940/schedule-13d-a/0001104659-26-070195","accession_number":"0001104659-26-070195","importance":70},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — ProQR Therapeutics N.V. — 2026-06-03","url_slug":"/sec/cik-0001612940/4/0001104659-26-070090","accession_number":"0001104659-26-070090","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"3","title":"3 — ProQR Therapeutics N.V. — 2026-06-02","url_slug":"/sec/cik-0001612940/3/0001104659-26-069449","accession_number":"0001104659-26-069449","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-06-02","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-069450","accession_number":"0001104659-26-069450","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-05-12","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-058980","accession_number":"0001104659-26-058980","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"6-K","title":"6-K — ProQR Therapeutics N.V. — 2026-05-12","url_slug":"/sec/cik-0001612940/6-k/0001104659-26-058981","accession_number":"0001104659-26-058981","importance":30}]}